Cargando…

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies

Detalles Bibliográficos
Autores principales:	Arasanz, Hugo, Zuazo, Miren, Vera, Ruth, Kochan, Grazyna, Escors, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356145/ https://www.ncbi.nlm.nih.gov/pubmed/30713587 http://dx.doi.org/10.2217/lmt-2018-0014

Ejemplares similares

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

The intracellular signalosome of PD-L1 in cancer cells
por: Escors, David, et al.
Publicado: (2018)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

PD1 signal transduction pathways in T cells
por: Arasanz, Hugo, et al.
Publicado: (2017)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
por: Arasanz, Hugo, et al.
Publicado: (2020)

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
por: Arasanz, Hugo, et al.
Publicado: (2020)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors
por: Arasanz, Hugo, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2023)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Metabolic predictors of response to immune checkpoint blockade therapy
por: Shorer, Ofir, et al.
Publicado: (2023)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
por: Echaide, Miriam, et al.
Publicado: (2022)

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

PD-L1, a Master Regulator of Immunity 2.0
por: Kochan, Grazyna
Publicado: (2023)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
por: Hong, Dong-Chun, et al.
Publicado: (2023)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l8rj6263qq0tcum2bhrtcibff4